Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2004

View Archived Issues

Ferring acquires Dupomar

New adenoviral vector for cystic fibrosis gene therapy identified

Genentech reports R&D highlights

Evotec OAI enters into medicinal chemistry collaboration

Menarini presents new bradykinin B2 antagonists for inflammatory and allergic disorders

Schering AG claims novel SERM for infertility, menopausal complaints, etc.

New 11beta-HSD1 inhibitors for diabetes, obesity, etc. covered by Merck patent

Memantine reported to enhance the beneficial effects of donepezil in moderate to severe AD

Novel caspase 1 inhibitors identified by Sunesis researchers

GSK presents another series of antibacterial PDF inhibitors

Dose-dependent improvements found with solifenacin in urinary incontinence

New histamine H3 antagonists prepared and tested by Schering-Plough team

Lilly scientists design new prodrugs of mGluR2 agonists

Albendazole reported effective in reducing seizures in patients with neurocysticercosis

New MRI agents for the diagnosis of tumors designed at Bracco

Update on Ushercell and Usherdex-4

Fast track designation for VaxGen's rPA-102

Zevalin radioimmunotherapy receives European approval

Approval for generic metoprolol tartrate

Micrologix Biotech discusses regulatory path for MBI-226 with FDA

Moscow sites open in phase II Liprostin trial

Onyvax and Mayo Clinic to develop cancer vaccines for ovarian cancer

SGN-30 enters new phase II study

German bone graft study commences for Aastrom's TRCs

XMP-629 enters phase II for acne

Enrollment completed in phase I Psoraxine trial

European approval for Mononine continuous intravenous infusion

Quigley Pharma provides update on research activities

Metabolex announces extension of collaboration focused on insulin secretion defects in diabetes

Neurochem forms alliances for its Alzheimer's disease synthetic vaccine program

Therapeutic benefits of cinacalcet in primary hyperparathyroidism

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...